ZEJULA (niraparib) Patient Assistance Program
Don’t let the high cost of brand specialty PARP inhibitor therapy stand between you and the treatment you need. We help eligible patients access Zejula (niraparib) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Zejula (niraparib) is FDA-approved as first-line maintenance therapy for advanced ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy, regardless of BRCA mutation status. It is also approved for second-line maintenance in BRCA-mutated recurrent ovarian cancer.
- Without assistance, the retail cost commonly runs approximately $14,000–$17,000 per 30-day supply at the standard 200–300 mg daily dose.
- Through AffordMyPrescriptions, qualifying patients can access Zejula for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic version of Zejula available in the U.S. as of 2026.
What Is Zejula Prescription Assistance Program?
The Zejula Prescription Assistance Program is a manufacturer-sponsored initiative that provides Zejula at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for ovarian cancer patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology-team coordination, BRCA mutation testing documentation (where required), specialty pharmacy logistics, blood-count monitoring schedules, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification — so you focus on your treatment, not paperwork.
Pharmacy Price Comparison
- Without assistance, Zejula costs roughly $14,000–$17,000 per 30-day supply. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$16,500.00 | Save ~$16,430/mo |
| CVS Pharmacy | ~$17,000.00 | Save ~$16,930/mo |
| Walmart | ~$15,200.00 | Save ~$15,130/mo |
| Costco | ~$14,800.00 | Save ~$14,730/mo |
| GoodRx Best Price | ~$14,000.00 | Save ~$13,930/mo |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. Afford My Prescriptions Advocacy Service bypasses retail pricing by using drug manufacturer programs to secure your medication for you—independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Zejula Prescription Program?
The Patient Assistance Program is free to apply for and provides Zejula at no medication cost if approved. But the process involves detailed applications, oncology-team coordination, BRCA mutation testing documentation, specialty pharmacy logistics, blood-count monitoring, and ongoing renewal management. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Zejula:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Cards expire and require constant renewal
- Subject to strict monthly or annual maximum savings caps
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- Up to 12 months of medication at no cost, renewable
- Medication supplied directly from the manufacturer
- We manage all paperwork, refills, and renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Zejula assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Zejula Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Alrex:
Zejula (niraparib) is an oral PARP inhibitor used as maintenance therapy in ovarian cancer following platinum-based chemotherapy. It is approved both for first-line maintenance (regardless of BRCA mutation status) and for second-line maintenance in BRCA-mutated recurrent disease. It is taken as oral capsules once daily.
How it works:
PARP (poly-ADP-ribose polymerase) is an enzyme that helps repair single-strand DNA breaks. Most cells have multiple DNA-repair mechanisms, but cancer cells with BRCA mutations or other homologous recombination deficiencies (HRD) rely heavily on PARP to repair DNA damage.
Zejula inhibits PARP, blocking single-strand DNA repair. In normal cells, alternative repair pathways take over. But in BRCA-mutated or HRD cancer cells, those alternative pathways are also impaired — so DNA damage accumulates and the cancer cell dies. This ‘synthetic lethality’ approach makes PARP inhibitors particularly effective in BRCA-mutated and HRD-positive cancers, but Zejula has shown benefit even in BRCA-wildtype patients in the first-line maintenance setting.
Form and use:
Zejula is taken by mouth once daily, with or without food. The starting dose is weight- and platelet-count-based: 200 mg daily for patients <77 kg or with platelets <150,000/μL, or 300 mg daily for patients ≥77 kg with platelets ≥150,000/μL. Treatment continues until disease progression or unacceptable toxicity. Take it at roughly the same time each day; bedtime is preferred to reduce nausea.
Generic availability:
There is no FDA-approved generic version of Zejula in the U.S. as of 2026. Other PARP inhibitors are FDA-approved for ovarian cancer (olaparib/Lynparza, rucaparib/Rubraca) — whether one is a clinical fit depends on the indication, biomarker status (BRCA, HRD), prior treatments, and tolerability.
Warnings:
Important warnings include myelodysplastic syndrome and acute myeloid leukemia (rare but serious — requires monitoring), bone marrow suppression (anemia, thrombocytopenia, neutropenia — requiring frequent blood-count monitoring), hypertension and hypertensive crisis, posterior reversible encephalopathy syndrome (PRES), and embryo-fetal toxicity. Blood counts must be checked weekly for the first month, then monthly. Tell your oncology team about new fatigue, easy bruising, headaches, or vision changes.
FAQ (Frequently Asked Questions)
How Much Does Zejula Cost Without Insurance?+
The retail price commonly runs $14,000–$17,000 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Zejula at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Do I Need BRCA Mutation Testing To Take Zejula?+
Not for first-line maintenance — Zejula is approved for first-line maintenance in advanced ovarian cancer regardless of BRCA mutation status (although patients with BRCA mutations or homologous recombination deficiency tend to derive greater benefit). For second-line maintenance in recurrent disease, BRCA mutation status (germline or somatic) is required for the approved indication.
Are There Other PARP Inhibitors I Should Know About?+
Yes. Other PARP inhibitors approved for ovarian cancer include olaparib (Lynparza) and rucaparib (Rubraca). Each has slightly different approved indications, dosing, and side-effect profiles. Whether one is a better fit depends on the indication, biomarker status, prior treatments, and tolerability. We mention this directly because if a different PARP inhibitor on a more accessible assistance pathway would work, that may be a better path.
Why Is Frequent Blood-Count Monitoring Required?+
Zejula commonly causes bone marrow suppression — particularly thrombocytopenia (low platelets), anemia, and neutropenia — especially in the first 2–3 months of treatment. Blood counts are checked weekly for the first month, every 2 weeks for months 2–3, then monthly. Dose reductions or treatment interruptions are sometimes needed to manage these side effects.
Can I Get Zejula Through The PAP If I Have Medicare?+
Yes. Medicare Part D beneficiaries can typically qualify for Zejula Patient Assistance, especially if you face specialty-tier copays you cannot afford. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?+
If your initial application is denied, we explore alternatives — the manufacturer’s copay savings program if you have commercial insurance, independent foundations such as the Ovarian Cancer Research Alliance, National Ovarian Cancer Coalition, PAN Foundation, or HealthWell Foundation, or asking your oncology team whether a different PARP inhibitor (olaparib, rucaparib) would be appropriate. If we cannot find a path, you will not be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Zejula, our team may be able to help you access assistance programs designed to make brand specialty PARP inhibitor therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.